High serum miR-183 level is associated with poor responsiveness of renal cancer to natural killer cells

References

Page 1

	Year	Citations
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial Sally Arai, Richard Meagher, Michelle L. Swearingen, Cytotherapy Cancer ImmunosurveillanceGenitourinary CancerImmunotherapyMedicineImmunology	2008	423
MicroRNA miR-183 Functions as an Oncogene by Targeting the Transcription Factor <i>EGR1</i> and Promoting Tumor Cell Migration Aaron L. Sarver, Lihua Li, Subbaya Subramanian Cancer Research	2010	279
TGF-β–inducible microRNA-183 silences tumor-associated natural killer cells Sarah S. Donatelli, Junmin Zhou, Danielle L. Gilvary, Proceedings of the National Academy of Sciences Inhibits Natural KillerCancer ImmunosurveillanceHuman Nk CellsCell SignalingMedicine	2014	210
Endothelial Progenitor Cell-Derived Microvesicles Improve Neovascularization in a Murine Model of Hindlimb Ischemia Andrea Ranghino, Vincenzo Cantaluppi, Cristina Grange, International Journal of Immunopathology and Pharmacology	2012	158
Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging Judith Eckl, Alexander Büchner, Petra U. Prinz, Journal of Molecular Medicine UrologyGenitourinary CancerImmunologyPathologyCancer Genomics	2011	127
microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer Keisuke Ueno, Hiroshi Hirata, Varahram Shahryari, British Journal of Cancer	2013	119
A Ten-MicroRNA Signature Identified from a Genome-Wide MicroRNA Expression Profiling in Human Epithelial Ovarian Cancer Lin Wang, Miaojun Zhu, Ai‐Min Ren, PLoS ONE Prognostic BiomarkersCancer DetectionEpithelial Ovarian CancerMedicineTen-microrna Signature	2014	114
Interleukin-2 in the treatment of renal cancer. Kim Margolin PubMed	2000	109
Immunotherapy of Advanced Malignancy by Direct Gene Transfer of an Interleukin-2 DNA/DMRIE/DOPE Lipid Complex: Phase I/II Experience Evanthia Galanis, E. M. Hersh, Alison Stopeck, Journal of Clinical Oncology	1999	99
Therapeutic Vaccination against Metastatic Carcinoma by Expression-Modulated and Immunomodified Autologous Tumor Cells: A First Clinical Phase I/II Trial Burghardt Wittig, Angela Märten, Tomislav Dorbic, Human Gene Therapy	2001	86

Page 1